MariMed Inc. (OTCMKTS:MRMD) Short Interest Down 81.7% in January

MariMed Inc. (OTCMKTS:MRMD) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totaling 1,025 shares, a drop of 81.7% from the December 31st total of 5,595 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 945,496 shares, the short-interest ratio is presently 0.0 days. Based on an average daily trading volume, of 945,496 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on MRMD shares. Ventum Cap Mkts lowered MariMed from a “strong-buy” rating to a “hold” rating in a report on Friday, November 7th. Zacks Research raised shares of MariMed from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

MariMed Trading Down 2.0%

Shares of OTCMKTS MRMD traded down $0.00 during trading hours on Wednesday, hitting $0.09. The company’s stock had a trading volume of 241,211 shares, compared to its average volume of 449,146. The stock has a market cap of $33.74 million, a price-to-earnings ratio of -2.13 and a beta of 1.04. The company has a debt-to-equity ratio of 1.34, a quick ratio of 0.35 and a current ratio of 1.06. The business has a 50-day simple moving average of $0.09 and a 200-day simple moving average of $0.12. MariMed has a 12 month low of $0.07 and a 12 month high of $0.23.

MariMed (OTCMKTS:MRMD) last issued its earnings results on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The business had revenue of $40.76 million for the quarter, compared to the consensus estimate of $42.15 million. MariMed had a negative return on equity of 14.67% and a negative net margin of 11.36%.

MariMed Company Profile

MariMed Inc is a multi?state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult?use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre?rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.